Open an account

F/M Emerald Life Sciences Innovation ETF

LFSC · ETF

$41.59−$0.9867 (−2.32%)TodayMarket closed ·
Prev close $42.58

About LFSC

LFSC was created on 2024-10-30 by F/m. The fund's investment portfolio concentrates primarily on health care equity. The ETF currently has 116.79m in AUM and 39 holdings. LFSC is an actively managed ETF that targets US health care and biotechnology companies identified to have promising life sciences opportunities.

Issuer
F/m
Expense ratio
0.54%
Assets under management
$122.49M
Inception
Oct 30, 2024
Asset class
Equity
Website
fminvest.com

LFSC key statistics

Price-earnings ratio
0.00
Average volume
3.68K
Volume
763
Open price
$42.17
High today
$42.17
Low today
$41.59
52 Week high
$48.78
52 Week low
$30.69

F/M Emerald Life Sciences Innovation ETF (LFSC) at a glance

As of Oct 23, 2026, F/M Emerald Life Sciences Innovation ETF (LFSC) shares are priced at $41.59, giving the company a price-to-earnings ratio of 0.00.

Today the fund has traded between $41.59 and $42.17. The current price is 0.0% above the day's low and 1.4% below its high.

Volume so far is 763 shares, below the average of 3.68K shares a day.

Over the past year F/M Emerald Life Sciences Innovation ETF has ranged from $30.69 to $48.78, and now sits 60% of the way up that range.

LFSC news

  • Vandana Singh

    Cogent Biosciences Stock Climbs After FDA Accepts Key Drug Application

  • Press releaseBusiness Wire

    Shining a Light on New Investment Opportunities: Small Caps Emerge from the Shadows at the Groundhog Investment Conference

  • Press releaseBusiness Wire

    Emerald Advisers and F/m Investments Announce the Launch of the F/m Emerald Life Sciences Innovation ETF (LFSC)

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.